Peptide record

TPDB09200

Ascaphin-8 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09200
Ascaphin-8
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 AI4AVP DRAVP 2.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 19-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GFKDLLKGAAKALVKTVLF
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C97H163N23O23
RNCEQHIMPSWY
LK
2019.50
10.55
4
1
11
+3
-0.40
0.737
128.42
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
1
Residue Composition
number
3
A
0
R
0
N
1
D
0
C
0
E
0
Q
2
G
0
H
0
I
4
L
4
K
0
M
2
F
0
P
0
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 4 K: 4 M: 0 F: 2 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
19 reviewed residue count
C97H163N23O23 sequence-only estimate (linear, free termini)
2019.50 sequence-only estimate (linear, free termini)
10.55 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
-0.40 sequence-only estimate (linear, free termini)
0.737 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Not Available Activity
Free Activity
Antibacterial Activity
Coastal Tailed Frog,Ascaphus truei, Pacific Northwest, USA, North America Activity
Evidence Records 54 records
Evidence 1 Activity

Activity

MIC
Antibacterial
6 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 2 Activity

Activity

MIC
Antibacterial
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 3 Activity

Activity

MIC
Antibacterial
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 4 Activity

Activity

MIC
Antibacterial
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 5 Activity

Activity

MIC
Antibacterial
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP DRAMP

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 6 Activity

Activity

MIC
Antibacterial
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP DRAMP

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 7 Activity

Activity

MIC
Antibacterial
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP DRAMP

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 8 Activity

Activity

MIC
Antibacterial
25 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 9 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP DRAMP

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 10 Activity

Activity

Not Available
Anticancer

Target

Not Available
Not Available
Not Available

Assay & Model

Not Available
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2004

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 11 Activity

Activity

MIC
Antifungal
6 µM

Target

Escherichia coli

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 12 Activity

Activity

MIC
Antifungal
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 13 Activity

Activity

MIC
Antifungal
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 14 Activity

Activity

MIC
Antifungal
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 15 Activity

Activity

MIC
Antifungal
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 16 Activity

Activity

MIC
Antifungal
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 17 Activity

Activity

MIC
Antifungal
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 18 Activity

Activity

MIC
Antifungal
25 µM

Target

Candida albicans

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 19 Activity

Activity

MIC
Antifungal
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 20 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 21 Activity

Activity

MIC
Antiparasitic
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 22 Activity

Activity

MIC
Antiparasitic
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 23 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 24 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP 3.0 DRAMP

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 25 Activity

Activity

MIC
Antiparasitic
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP 3.0 DRAMP

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 26 Activity

Activity

MIC
Antiparasitic
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP 3.0 DRAMP

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 27 Activity

Activity

MIC
Antiparasitic
25 µM

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 28 Activity

Activity

MIC
Antiparasitic
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP 3.0 DRAMP

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 29 Activity

Activity

MIC
Antiviral
6 µM

Target

Escherichia coli

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae
Evidence 30 Activity

Activity

MIC
Antiviral
3 µM

Target

Staphylococcus aureus

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermid
Evidence 31 Activity

Activity

MIC
Antiviral
13 µM

Target

Pseudomonas aeruginosa

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcu
Evidence 32 Activity

Activity

MIC
Antiviral
6 µM

Target

Enterobacter cloacae

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E
Evidence 33 Activity

Activity

MIC
Antiviral
6 µM

Target

Klebsiella pneumoniae

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

li (MIC 6 uM) and S. aureus (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), an
Evidence 34 Activity

Activity

MIC
Antiviral
6 µM

Target

Staphylococcus epidermidis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

s (MIC 3 uM), P. aeruginosa (MIC 13 uM), E. cloacae (MIC 6 uM), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM).
Evidence 35 Activity

Activity

MIC
Antiviral
50 µM

Target

Enterococcus faecalis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

), K. pneumoniae (MIC 6 uM), S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et
Evidence 36 Activity

Activity

MIC
Antiviral
25 µM

Target

Candida albicans

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

S. epidermidis (MIC 6 uM), Streptococcus Group B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Age
Evidence 37 Activity

Activity

MIC
Antiviral
3.1 µM

Target

MRSA USA300

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

p B (MIC 6 uM), E. faecalis (MIC 50 uM), and C. albicans (MIC 25 uM). Also active against MRSA USA300 (MIC 3.1 uM) (Menousek J et al 2012 Int J Antimicrob Agents 39:402). The peptide also inhibited Human
Evidence 38 Activity

Activity

HC50
Hemolysis
50 µM
[Ref.15207717]HC50=50 µM against human erythrocytes

Target

human erythrocytes

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Biochem Biophys Res Commun. 2004 Jul 16 320(1):170-175.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 39 Activity

Activity

50% Hemolysis
Toxicity
55 µM
Hemolytic Cytotoxic
50% Hemolysis | 55 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The ascaphins: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei. | Biochem Biophys Res Commun | 2004
Evidence 40 Activity

Activity

50% Cell death
Toxicity
7 µM
Cytotoxic
50% Cell death | 7 | µM | target cell: Mouse fibroblasts L929

Target

Mouse fibroblasts L929

Source & Reference

NA
DBAASP
Design of potent, non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin-8 and peptide XT-7. | Chem Biol Drug Des | 2008
Evidence 41 Activity

Activity

50% Cell death
Toxicity
2.9 µM
Cytotoxic
50% Cell death | 2.9 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. | Antimicrob Agents Chemother | 2010
Evidence 42 Activity

Activity

14.72±0.79% Hemolysis
Toxicity
8 µM
Hemolytic Cytotoxic
14.72±0.79% Hemolysis | 8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 43 Activity

Activity

28.10±4.76% Hemolysis
Toxicity
16 µM
Hemolytic Cytotoxic
28.10±4.76% Hemolysis | 16 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 44 Activity

Activity

54.35±4.5% Hemolysis
Toxicity
32 µM
Hemolytic Cytotoxic
54.35±4.5% Hemolysis | 32 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 45 Activity

Activity

91.90±6.36% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
91.90±6.36% Hemolysis | 64 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 46 Activity

Activity

100% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
100% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Encrypted Antimicrobial Peptides from Plant Proteins. | Sci Rep | 2017
Evidence 47 Activity

Activity

LC90
Toxicity
64 µg/mL
Cytotoxic
LC90 | 64 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 48 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The ascaphins: a family of antimicrobial peptides from the skin secretions of the most primitive extant frog, Ascaphus truei. | Biochem Biophys Res Commun | 2004
Evidence 49 Activity

Activity

10% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 50 Activity

Activity

LC
Toxicity
128 µg/mL
Cytotoxic
LC | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 51 Activity

Activity

LC90
Toxicity
128 µg/mL
Cytotoxic
LC90 | 128 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 52 Activity

Activity

LC50
Toxicity
100 µg/mL
Cytotoxic
LC50 | 100 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo | J Med Chem | 2022
Evidence 53 Activity

Activity

HC50
Toxicity
50 µM
Hemolytic
Hemolytic_activity: [Ref.15207717]HC50=50 µM against human erythrocytes

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochem Biophys Res Commun. 2004 Jul 16 320(1):170-175.
Evidence 54 Hemolysis

Activity

50 µM
HC50
[Ref.15207717]HC50=50 µM against human erythrocytes
Hemolysis

Target

human erythrocytes

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Biochem Biophys Res Commun. 2004 Jul 16 320(1):170-175.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.